Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14112514
Abstract: Introduction: Molnupiravir and Nirmatrelvir/r (NMV-r) have been proven to reduce severe Coronavirus Disease 2019 (COVID-19) in unvaccinated high-risk individuals. Data regarding their impact in fully vaccinated vulnerable subjects with mild-to-moderate COVID-19 are still limited, particularly… read more here.
Keywords: early access; composite outcome; high risk; risk outpatients ... See more keywords
In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0118
Abstract: SOURCE CITATION Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022;10:1160-8. 36228639. read more here.
Keywords: covid neither; risk outpatients; high risk; colchicine ... See more keywords